{"name": "Lundbeck",
 "permalink": "lundbeck",
 "crunchbase_url": "http://www.crunchbase.com/company/lundbeck",
 "homepage_url": "http://www.lundbeck.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": null,
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "information@lundbeck.com",
 "phone_number": "45-36-30-13-11",
 "description": "Research-based company",
 "created_at": "Thu Jun 11 10:53:28 UTC 2009",
 "updated_at": "Sat Mar 30 05:49:13 UTC 2013",
 "overview": "\u003Cp\u003EThey are a research-based company. They engage in research to find new drugs for treatment of CNS disorders, including depression, schizophrenia, Alzheimer\u00e2\u20ac\u2122s disease, Parkinson\u00e2\u20ac\u2122s disease and insomnia.\nThese are serious disorders. They affect not only patients, but also their families and friends. Besides the stress of having a CNS disorder, patients are often exposed to prejudice because, in many sections of society, there is still far too little understanding of how adversely a CNS disorder affects an individual\u00e2\u20ac\u2122s life.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       57],
      "assets/images/resized/0004/8012/48012v1-max-150x150.png"],
     [[210,
       81],
      "assets/images/resized/0004/8012/48012v1-max-250x250.png"],
     [[210,
       81],
      "assets/images/resized/0004/8012/48012v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chief Executive Officer",
    "person":
     {"first_name": "Ulf",
      "last_name": "Wiinberg",
      "permalink": "ulf-wiinberg",
      "image":
       {"available_sizes":
         [[[90,
            65],
           "assets/images/resized/0004/8116/48116v1-max-150x150.jpg"],
          [[90,
            65],
           "assets/images/resized/0004/8116/48116v1-max-250x250.jpg"],
          [[90,
            65],
           "assets/images/resized/0004/8116/48116v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Executive Vice President",
    "person":
     {"first_name": "Peter",
      "last_name": "H\u00c3\u00b8ngaard Andersen",
      "permalink": "peter-hngaard-andersen",
      "image":
       {"available_sizes":
         [[[90,
            73],
           "assets/images/resized/0004/8119/48119v1-max-150x150.jpg"],
          [[90,
            73],
           "assets/images/resized/0004/8119/48119v1-max-250x250.jpg"],
          [[90,
            73],
           "assets/images/resized/0004/8119/48119v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Executive Vice President",
    "person":
     {"first_name": "Lars",
      "last_name": "Bang",
      "permalink": "lars-bang",
      "image":
       {"available_sizes":
         [[[90,
            65],
           "assets/images/resized/0004/8120/48120v1-max-150x150.jpg"],
          [[90,
            65],
           "assets/images/resized/0004/8120/48120v1-max-250x250.jpg"],
          [[90,
            65],
           "assets/images/resized/0004/8120/48120v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [{"funding_round":
     {"round_code": "unattributed",
      "source_url": "http://www.fiercebiotech.com/story/proximagen-polishes-its-cns-rep-16m-lundbeck-deal/2011-09-29?utm_medium=rss\u0026utm_source=rss",
      "source_description": "Proximagen polishes its CNS rep with $16M Lundbeck deal",
      "raised_amount": 16000000.0,
      "raised_currency_code": "USD",
      "funded_year": 2011,
      "funded_month": 9,
      "funded_day": 29,
      "company":
       {"name": "Proximagen",
        "permalink": "proximagen",
        "image":
         {"available_sizes":
           [[[150,
              39],
             "assets/images/resized/0004/9242/49242v1-max-150x150.png"],
            [[210,
              55],
             "assets/images/resized/0004/9242/49242v1-max-250x250.png"],
            [[210,
              55],
             "assets/images/resized/0004/9242/49242v1-max-450x450.png"]],
          "attribution": null}}}}],
 "acquisition": null,
 "acquisitions":
  [{"price_amount": 900000000.0,
    "price_currency_code": "USD",
    "term_code": null,
    "source_url": "http://www.reuters.com/article/pressRelease/idUS126648+19-Mar-2009+BW20090319",
    "source_description": "GTCR Completes the Sale of Ovation Pharmaceuticals to Lundbeck",
    "acquired_year": 2009,
    "acquired_month": 3,
    "acquired_day": 19,
    "company":
     {"name": "Ovation Pharmaceuticals",
      "permalink": "ovation-pharmaceuticals",
      "image":
       {"available_sizes":
         [[[150,
            39],
           "assets/images/resized/0014/7546/147546v1-max-150x150.png"],
          [[250,
            65],
           "assets/images/resized/0014/7546/147546v1-max-250x250.png"],
          [[311,
            82],
           "assets/images/resized/0014/7546/147546v1-max-450x450.png"]],
        "attribution": null}}}],
 "offices":
  [{"description": "Headquarters",
    "address1": "Ottiliavej 9",
    "address2": "DK 2500 Copenhagen - Valby",
    "zip_code": "",
    "city": "",
    "state_code": null,
    "country_code": "DNK",
    "latitude": 55.6581791,
    "longitude": 12.5164992}],
 "milestones":
  [{"description": "Headed into PhIII, Lundbeck scores $825M Alzheimer's drug pact with Otsuka\r\n\r\nRead more: Headed into PhIII, Lundbeck scores $825M Alzheimer's drug pact with Otsuka - FierceBiotech http://www.fiercebiotech.com/story/headed-phiii-lundbeck-scores-825m-alzhei",
    "stoned_year": 2013,
    "stoned_month": 3,
    "stoned_day": 26,
    "source_url": "http://www.fiercebiotech.com/story/headed-phiii-lundbeck-scores-825m-alzheimers-drug-pact-otsuka/2013-03-26?utm_source=rss\u0026utm_medium=rss",
    "source_text": "",
    "source_description": "Headed into PhIII, Lundbeck scores $825M Alzheimer's drug pact with Otsuka  Read more: Headed into PhIII, Lundbeck scores $825M Alzheimer's drug pact with Otsuka - FierceBiotech http://www.fiercebiotech.com/story/headed-phiii-lundbeck-scores-825m-alzheime",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Lundbeck",
      "permalink": "lundbeck"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        94],
       "assets/images/resized/0004/8013/48013v1-max-150x150.jpg"],
      [[250,
        157],
       "assets/images/resized/0004/8013/48013v1-max-250x250.jpg"],
      [[450,
        283],
       "assets/images/resized/0004/8013/48013v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}